截至2025年6月19日 09:37，恒生医疗保健指数(HSHCI)强势上涨1.32%，成分股信达生物(01801)上涨5.53%，晶泰控股(02228)上涨4.37%，诺诚健华(09969)上 涨3.46%，亚盛医药-B(06855)，美中嘉和(02453)等个股跟涨。恒生医疗ETF(513060)上涨1.26%，最新价报0.56元。流动性方面，恒生医疗ETF盘中换手 3.37%，成交2.71亿元。拉长时间看，截至6月18日，恒生医疗ETF近1周日均成交28.68亿元，居可比基金第一。 2025年6月20日-23日，第85届美国糖尿病协会科学会议（ADA）将在美国芝加哥召开，ADA大会是糖尿病研究与治疗领域的权威学术盛会之一，预计GLP-1 类药物的多靶点升级与减重治疗新策略将受到广泛关注。此次会议将有多家国内医药企业展示其在相关领域的最新研究成果和进展，建议关注。 国开证券指出，年初以来，创新药板块在政策、出海、业绩等多方面推动下，市场关注度高，叠加此前已经过较长时间调整，市场表现较为抢眼。目前个股 表现虽出现些许分化，但我们仍维持此前观点，认为创新药仍是行业最重要的投资主线之一。人工智能技术快速发展，医 ...

Summary of the Conference Call for Innovent Biologics Company Overview - **Company**: Innovent Biologics - **Industry**: Innovative Pharmaceuticals Key Points and Arguments Industry Dynamics - The innovative drug sector is experiencing a rebound driven by changes in demand and policy, with Hong Kong's innovative drug sector valuations rising, albeit limited by profit growth [2][3] - The sector is at a historical low valuation, with recent data from the ASCO conference showcasing the global competitiveness of domestic innovative drug companies [3] Financial Performance - Innovent Biologics reported strong revenue performance, with projected revenue exceeding 8.2 billion yuan in 2024, representing a 40% year-on-year growth [2][6] - Q4 product revenue is expected to surpass 2 billion yuan, showing a 25% increase year-on-year [2][6] Product Pipeline and Commercialization - The company anticipates commercializing 14 products within the next one to two years, with several entering NDA and NMPA reviews or critical clinical studies [2][7] - Expected new revenue streams from products like IGF-1R and peptide I23P19 are projected to help achieve EBITDA breakeven by 2025, with domestic product revenue reaching 20 billion yuan by 2027 [2][7] Key Products and Innovations - The PD-1/IL-2 fusion protein IBI363 has shown significant efficacy in treating IO-resistant non-small cell lung cancer and third-line colorectal cancer, with global peak sales potential estimated at 10 billion USD [2][9][10] - The drug's design enhances efficacy while reducing toxicity, showing promising data in clinical trials [9][10] Market Opportunities - The GIP/GLP-1 dual receptor agonist, Masitide, is expected to be approved by 2025, providing a new growth avenue for the company [4][12] - Innovent's comprehensive layout in the metabolic field, including the P9 monoclonal antibody, is expected to drive sales growth [4][13] Competitive Landscape - The company is well-positioned in the autoimmune sector with innovative drugs like IL-23 P19, which is anticipated to gain market approval soon [4][16] - The market for thyroid eye disease is significant, with approximately 4 million patients in China, and Innovent's IGF-1R antibody showing promising results [14] Valuation and Future Outlook - Innovent's projected revenue of 20 billion yuan by 2027 is seen as a target, with potential peak sales reaching 30 billion yuan based on ongoing clinical developments [8] - The company is suitable for DCF valuation rather than PS, as its early-stage assets have not been fully assessed [8] - The future outlook remains optimistic, with numerous catalysts expected from clinical data releases in the coming years [18] Conclusion - Innovent Biologics is positioned as a strong candidate for medium to long-term investment, supported by robust revenue growth, a promising product pipeline, and favorable market dynamics [18]

Investment Rating - The report assigns an "Overweight" (OW) rating to Innovent, Akeso, and Kelun Biotech, indicating an expectation that these stocks will outperform the average total return of their coverage universe [4][7]. Core Insights - Innovent has shown strong investor interest, with a recent stock increase of approximately 3% following a share sale by Lilly Asia Ventures. The company achieved its first-ever non-IFRS positive profit and EBITDA in 2024, and this trend is expected to continue into 2025 and beyond. Innovent is anticipated to secure an outlicensing deal for IBI363, which holds significant value in the immuno-oncology therapy space [4]. - Akeso's share price rose by 10% on June 10, attributed to comments from its U.S. partner, Summit, regarding avoiding a cash raise and manufacturing Ivonescimab in-house. Summit plans to recruit participants for global trials from multiple regions, including China, the U.S., and the EU. The BLA filing strategy for HARMONi is still under discussion [4]. - Kelun Biotech completed an equity raise and does not require additional cash due to solid reserves. Promising ASCO data for Sac-TMT in treating triple-negative breast cancer and non-squamous non-small cell lung cancer indicates a higher probability of success in Phase 3 trials. The domestic Phase 3 trial is enrolling patients rapidly, with potential for an interim analysis this year [4][5]. Summary by Company Innovent - Innovent's stock increased by ~3% after a secondary share placement by Lilly Asia Ventures, which still holds a ~2% stake. The company achieved its first non-IFRS positive profit and EBITDA in 2024, with expectations for continued growth in 2025. Anticipated catalysts include an outlicensing deal for IBI363 [4][5]. Akeso - Akeso's share price increased by 10% following positive comments from Summit, its U.S. partner. Summit is working on in-house manufacturing of Ivonescimab and plans to recruit trial participants from various regions. The BLA filing strategy for HARMONi is still being evaluated [4][5]. Kelun Biotech - Kelun Biotech completed an equity raise and has solid cash reserves. Promising data for Sac-TMT in treating specific cancers suggests a high probability of success in upcoming trials. The company is rapidly enrolling patients for a domestic Phase 3 trial, with potential for an interim analysis this year [4][5].

Core Viewpoint - The report from浦银国际 indicates that信达生物 (01801) has promising potential for international licensing of IBI363 and IBI343, particularly highlighting IBI363 as a potential solution for PD-1 resistance [1] Financial Projections - The projected net profit for the company is estimated to be 4.3 billion, 8.5 billion, and 18.9 billion for the years 2025, 2026, and 2027 respectively [1] - The target price has been raised to 95 HKD based on a DCF valuation model with an 8.5% WACC and a 3% perpetual growth rate [1] Clinical Data Insights - IBI363's mPFS in the 3mg/kg dose group for IO-treated sq-NSCLC has improved to 9.3 months, enhancing confidence in its development for lung squamous carcinoma [2] - In the same context, the 3mg/kg dose group showed better efficacy data compared to the ≤1.5mg/kg group, with higher cORR and longer mPFS [2] - IBI363 in combination with Bevacizumab showed a 15.1% cORR and a 4.7-month mPFS, with a notable 31.3% cORR and 7.4-month mPFS in the population without liver metastasis [3] - The single-agent mOS for IBI363 was reported at 16.1 months, with significant improvements in the mOS for both liver metastasis and non-liver metastasis groups [3] - For IBI343 in pancreatic cancer, the mOS has increased from 8.5 months to 9.1 months, while the mPFS remains consistent at 5.4 months [5] Additional Clinical Findings - IBI363 at a 1mg/kg Q2W dosage showed an mPFS of 5.7 months and an mOS of 14.8 months, significantly higher than real-world data for second-line therapies [4]

Core Viewpoint - The company has presented additional follow-up data for IBI363 and IBI343 at the ASCO conference, showing promising results that enhance confidence in their development, leading to an upward revision of the target price to HKD 95 and a reaffirmation of the "buy" recommendation [1][5]. Group 1: IBI363 Data Insights - The mPFS for the IBI363 3mg/kg dose group in IO-treated sq-NSCLC has been extended to 9.3 months, an improvement from the previously reported 7.3 months, indicating strong efficacy [2][3]. - In the EGFR wild-type adenocarcinoma (EGFRwt Ad-NSCLC), the mPFS remains consistent at 4.2 months, outperforming docetaxel's mPFS of 2.5-4 months [2]. - The company plans to initiate a Phase III registration clinical trial for IBI363 in 3L+ sq-NSCLC, with the 3mg/kg dose expected to be used [2]. Group 2: IBI343 and Other Data - IBI363 combined with bevacizumab shows a 15.1% cORR and a 4.7-month mPFS, with a notable 31.3% cORR and 7.4-month mPFS in the population without liver metastasis [3]. - The overall mOS for IBI363 monotherapy is reported at 16.1 months, with subgroup analysis showing mOS of 14.4 months for liver metastasis patients and 17.0 months for those without, both significantly higher than the 9.3 months for fruquintinib in 3L CRC [3]. - In melanoma, the IBI363 1mg/kg Q2W dose group shows mPFS of 5.7 months and mOS of 14.8 months, significantly better than real-world data [4]. Group 3: Financial Projections - The company forecasts peak sales of approximately HKD 2.5 billion for IBI363 and HKD 1.5 billion for IBI343 in China, adjusted for risk [5]. - Projected net profits for the company are estimated at HKD 430 million, HKD 850 million, and HKD 1.89 billion for the years 2025, 2026, and 2027, respectively [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 95, representing a potential upside of 17% from the current price of HKD 81.1 [2][9][10] Core Insights - The report highlights positive updates on IBI363 and IBI343, with IBI363 showing an extended median progression-free survival (mPFS) of 9.3 months in the 3 mg/kg dose group for IO-treated squamous non-small cell lung cancer (sq-NSCLC), enhancing confidence in its development for lung squamous carcinoma [1][7][10] - The company is expected to initiate Phase 3 registration clinical trials for IBI363 in the 3L+ sq-NSCLC setting, with the 3 mg/kg dose likely to be used [7][10] - Financial projections indicate a significant increase in revenue and net profit over the next few years, with expected revenues of RMB 11.7 billion in 2025 and a net profit of RMB 433 million [9][10] Financial Projections - Revenue is projected to grow from RMB 6.2 billion in 2023 to RMB 15.8 billion by 2027, with a compound annual growth rate (CAGR) of 36.2% [9][10] - The adjusted net profit is expected to turn positive in 2025, reaching RMB 1.03 billion by 2025 and RMB 2.66 billion by 2027 [9][10] - The report anticipates peak sales for IBI363 in China to reach approximately RMB 2.5 billion and for IBI343 to reach around RMB 1.5 billion, both on a risk-adjusted basis [10]

Investment Rating - The report maintains an "OUTPERFORM" rating for Innovent Biologics with a target price of HK$90.10, up from a previous target of HK$62.50 [2][10]. Core Insights - Innovent Biologics showcased its strong oncology R&D capabilities at the 2025 ASCO Annual Meeting, with eight studies selected for oral presentation, highlighting the efficacy and safety of IBI363 and IBI343 in various cancer types [3][15]. - The data presented for IBI363 in IO-pretreated advanced non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) supports its potential as a backbone therapy for future immuno-oncology treatments [4][16]. Financial Summary - Revenue projections for Innovent Biologics are set at RMB 11.86 billion for 2025, with a growth rate of 26% compared to the previous year [10][13]. - The company is expected to turn profitable in 2025, achieving a net profit of RMB 384 million, with further growth anticipated in subsequent years [10][13]. Clinical Data Highlights - IBI363 monotherapy demonstrated a median progression-free survival (mPFS) of 9.3 months in advanced NSCLC patients, outperforming standard therapies [5][19]. - In patients with MSS-type colorectal cancer, IBI363 showed a median overall survival (mOS) of 16.1 months, significantly longer than the typical 9-10 months seen with current treatments [8][20]. - The efficacy of IBI363 in treating acral and mucosal melanoma was also notable, with a confirmed objective response rate (ORR) of 23.3% in IO-refractory patients [9][22]. Valuation and Estimates - The report employs a DCF model for valuation, estimating a share price of HK$90.10 based on projected cash flows from 2026 to 2037 [10][12]. - The gross profit margin is expected to remain high, around 84% in the coming years, indicating strong operational efficiency [10][13].

Investment Rating - The report maintains an "OUTPERFORM" rating for Innovent Biologics with a target price of HK$90.10, up from a previous target of HK$62.50 [2][10]. Core Insights - Innovent Biologics showcased its strong oncology R&D capabilities at the 2025 ASCO Annual Meeting, with eight studies selected for oral presentation, highlighting the efficacy and safety of IBI363 and IBI343 in various cancer types [3][15][16]. - The data presented for IBI363 in advanced non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) indicates its potential as a backbone therapy for next-generation immuno-oncology treatments, demonstrating robust tumor responses and long-term survival benefits [4][16]. Financial Summary - Revenue projections for Innovent Biologics are set at RMB 11.86 billion for 2025, with a growth rate of 26% compared to the previous year, and expected to reach RMB 18.17 billion by 2027 [10][13]. - The company is projected to turn profitable in 2025, with a net profit of RMB 384 million, and further growth to RMB 1.77 billion by 2027 [10][13]. Clinical Data Highlights - IBI363 monotherapy showed a median progression-free survival (mPFS) of 9.3 months in advanced NSCLC, outperforming standard therapies [5][19]. - In MSS-type colorectal cancer patients, IBI363 demonstrated a median overall survival (mOS) of 16.1 months, significantly longer than the typical 9-10 months seen with current therapies [8][20]. - The efficacy of IBI363 in treating acral and mucosal melanoma was also notable, achieving a confirmed objective response rate (ORR) of 23.3% in a historically difficult-to-treat population [22].

Group 1 - Southbound funds net bought HKD 717 million in Hong Kong stocks on June 9, with notable net purchases in companies like Innovent Biologics (HKD 1.125 billion), Meituan (HKD 1.046 billion), and Li Auto (HKD 452 million) [1] - Tencent Holdings saw a significant net sell-off of HKD 2.141 billion, marking a continuous seven-day net sell totaling HKD 8.05292 billion [1] - Meituan has experienced a continuous net buy for 16 days, accumulating a total of HKD 17.52673 billion [1] Group 2 - Innovent Biologics' stock rose by 8% to HKD 79 per share, driven by positive clinical data presented at the ASCO annual meeting [5] - Goldman Sachs upgraded Innovent Biologics' risk-adjusted sales forecast for IBI363 from USD 1.4 billion to USD 3.2 billion, anticipating its market launch in 2028 [5] - Tencent Holdings' stock slightly increased by 0.58% to HKD 518 per share, with the company repurchasing 968,000 shares at prices ranging from HKD 513 to HKD 520.5 [5] Group 3 - Xiaomi Group's stock rose by 1.98% to HKD 54.15 per share, with over 250,000 units of the Xiaomi SU7 delivered [5]

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound capital, with a total net buy of 717 million HKD on June 9, 2023, indicating strong investor interest in certain stocks, particularly in the innovative pharmaceutical sector and local businesses like Meituan [1][2]. Group 1: Northbound Capital Inflows and Outflows - Northbound capital had a net buy of 12.47 billion HKD through the Shenzhen Stock Connect and a net sell of 5.3 billion HKD through the Shanghai Stock Connect [1]. - The stocks with the highest net inflows included Xinda Bio (01801), Meituan-W (03690), and Li Auto-W (02015) [1]. - The stocks with the highest net outflows were Tencent (00700), Xiaomi Group-W (01810), and Alibaba-W (09988) [1]. Group 2: Active Stocks and Their Performance - Meituan-W (03690) saw a net buy of 10.46 billion HKD, supported by strong fundamentals and a solid merchant base [5]. - Xinda Bio (01801) received a net buy of 7.73 billion HKD, benefiting from favorable developments in the pharmaceutical sector [4]. - Alibaba-W (09988) and Tencent (00700) faced significant net sells of 9.39 billion HKD and 21.41 billion HKD, respectively, due to concerns over capital expenditures and cloud revenue growth [6]. Group 3: Sector Trends and Insights - The innovative pharmaceutical sector is gaining traction, with Xinda Bio, Shiyao Group, and Sanofi Pharmaceutical receiving substantial net buys, reflecting a positive outlook for domestic innovative drugs [4]. - The automotive sector showed mixed results, with Li Auto-W (02015) gaining 4.52 billion HKD while Xiaomi Group-W (01810) faced a net sell of 14.52 billion HKD, indicating ongoing challenges in the industry [5]. - The banking sector, represented by China Bank (03988), attracted a net buy of 326.7 million HKD, driven by stable fundamentals and dividend attractiveness [6].